121 related articles for article (PubMed ID: 17504360)
1. Why do patients fail HIV therapy?
Waters L; Nelson M
Int J Clin Pract; 2007 Jun; 61(6):983-90. PubMed ID: 17504360
[TBL] [Abstract][Full Text] [Related]
2. Current management challenges in HIV: antiretroviral resistance.
Kuritzkes DR; Boyle BA; Gallant JE; Squires KE; Zolopa A
AIDS Read; 2003 Mar; 13(3):133-5, 138-42. PubMed ID: 12728868
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
4. Impact of resistance to antiretroviral therapy in the minority community.
Rodriguez AE; Campo RE; Gathe JC; Kwakwa HA
AIDS Read; 2004 Oct; 14(10 Suppl):S9-11. PubMed ID: 15497217
[TBL] [Abstract][Full Text] [Related]
5. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy.
Sax PE
AIDS Read; 2006 May; 16(5):265-75, 277-8. PubMed ID: 16764068
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Calza L; Manfredi R; Pocaterra D; Chiodo F
Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
[TBL] [Abstract][Full Text] [Related]
8. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
9. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
10. High antiretroviral drug adherence key in effort to avoid drug resistance. New study highlights its importance.
AIDS Alert; 2005 Mar; 20(3):25, 27-8. PubMed ID: 15789470
[TBL] [Abstract][Full Text] [Related]
11. Optimal drug treatment regimens for HIV depend on adherence.
Krakovska O; Wahl LM
J Theor Biol; 2007 Jun; 246(3):499-509. PubMed ID: 17320115
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
Lagnese M; Daar ES
Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
14. Advances in human immunodeficiency virus therapeutics.
Clay PG; Dong BJ; Sorensen SJ; Tseng A; Romanelli F; Antoniou T
Ann Pharmacother; 2006 Apr; 40(4):704-9. PubMed ID: 16551767
[TBL] [Abstract][Full Text] [Related]
15. Predicting and monitoring antiretroviral adherence.
Gross R
LDI Issue Brief; 2007; 13(2):1-4. PubMed ID: 18354853
[TBL] [Abstract][Full Text] [Related]
16. Improvements in antiretroviral therapy outcomes over calendar time.
Boyd MA
Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
[TBL] [Abstract][Full Text] [Related]
17. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Chetchotisakd P
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
[TBL] [Abstract][Full Text] [Related]
18. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
19. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
20. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
